Abstract
The aim of this randomized phase II study was to improve the treatment delays and discontinuations associated with bendamustine use by comparing the effect of Benda-14 (intravenous bendamustine, 120 mg/m2 on days 1 and 15, repeated every 4 weeks for a total of 6 cycles) with those of the standard treatment in relapsed indolent lymphoma and/or mantle cell lymphoma. Forty-six patients were randomly assigned to the treatments from September 2012 to February 2016. Treatment accomplishment rate and median relative dose intensity were similar in both arms: 38 and 63.4% in the Benda-14 arm and 41 and 66.3% in the standard treatment arm, respectively. The overall response rate and median progression-free survival, respectively, were 83% and 21.0 months for Benda-14, and 77% and 15.5 months for the standard treatment. Benda-14 induced favorable responses with less frequent hematological toxicities.
References
Dec 22, 1998·Journal of Cancer Research and Clinical Oncology·K HöffkenS Seeber
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Aug 15, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P SchöffskiA Ganser
Feb 24, 2001·Journal of Cancer Research and Clinical Oncology·R KathK Höffken
Oct 11, 2001·Anti-cancer Drugs·A Heider, N Niederle
Nov 30, 2002·Journal of Cancer Research and Clinical Oncology·Karl Bremer
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan W FriedbergBruce D Cheson
Nov 21, 2008·Cancer Science·Kensei TobinaiKeigo Endo
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D Cheson, Mathias J Rummel
Oct 29, 2009·Leukemia & Lymphoma·Peter MoosmannMario Bargetzi
Mar 13, 2010·Clinical Lymphoma, Myeloma & Leukemia·Bruce D ChesonMathias Rummel
Jul 16, 2010·Cancer Science·Ken OhmachiUNKNOWN Japanese Bendamustine Lymphoma Study Group
Feb 26, 2013·Lancet·Mathias J RummelUNKNOWN Study group indolent Lymphomas (StiL)
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoMaura Brugiatelli
Aug 1, 2013·The Oncologist·Wolfram Brugger, Michele Ghielmini
Mar 5, 2014·Blood·Ian W FlinnJohn M Burke
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sally F BarringtonBruce D Cheson
Oct 27, 2015·Blood Cancer Journal·H SaitoK Tobinai
Nov 26, 2015·Leukemia & Lymphoma·Bruce D ChesonPier Luigi Zinzani
Jan 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chan Yoon CheahMichael L Wang
Mar 19, 2016·Blood·Brad S Kahl, David T Yang
Jun 28, 2016·The Lancet Oncology·Laurie H SehnBruce D Cheson
Oct 14, 2016·Hematological Oncology·Anat Gafter-GviliLiat Vidal